Policymakers need to understand that Alzheimer’s disease and other dementias represent one of the largest and fastest-growing cost burdens in American health care. The total cost of dementia care in the United States is projected to reach $409 billion in 2026—and this figure will nearly triple to almost $1 trillion by 2050. Unlike many chronic diseases where costs stabilize, Alzheimer’s care costs are accelerating faster than inflation or population growth, driven by longer lifespans, earlier diagnosis, and new but expensive treatments. For context, a person diagnosed with Alzheimer’s at age 65 will incur a lifetime care cost of approximately $405,262 in 2024 dollars, with families shouldering 70% of that burden through unpaid labor and direct expenses.
The funding burden falls unevenly across payers. Medicare and Medicaid together cover about 64% of dementia costs—$263 billion in 2026—while individuals and families pay $103 billion out of pocket. This split is crucial for policymakers because it reveals a fundamental tension: the public programs that insure older Americans and low-income populations bear the largest financial load, yet coverage gaps and eligibility rules often force families to choose between medication, caregiving, and bankruptcy. Understanding this cost architecture is not optional for policymakers shaping health budgets, long-term care policy, or pharmaceutical regulations.
Table of Contents
- How Much Does Dementia Actually Cost Government Programs?
- The Hidden Burden: What Families Actually Pay
- The Budget Reality: Why Current Spending Cannot Continue
- Medicare Coverage: What It Includes and What Families Must Pay Separately
- Medicaid and Long-Term Care: The Program That Bears the Heaviest Load
- Federal Policy and Research Investment: The Case for Prevention
- Coverage Gaps and the Out-of-Pocket Reality
How Much Does Dementia Actually Cost Government Programs?
Government programs do not bear dementia costs equally. A person living with dementia incurs Medicare costs that are nearly three times higher than those for older adults without dementia, and medicaid costs that are 22 times higher. For policymakers managing state Medicaid budgets, this multiplier effect means that even modest growth in dementia prevalence translates into severe fiscal pressure. A state that insures 100,000 people over 65 might find that just 15,000 dementia diagnoses consume a disproportionate share of its Medicaid long-term care budget, potentially crowding out funding for other populations. The sheer scale makes planning difficult.
In 2026, just two programs—Medicare and Medicaid—will spend $263 billion on dementia care. By comparison, the entire annual budget of the National Institutes of Health is roughly $47 billion. Policymakers at the federal level must choose between funding research into prevention and treatment (which might reduce future costs) and funding current care (which is guaranteed and growing). States face a similar but more urgent choice: a person entering a nursing home with advanced Alzheimer’s may spend 5 to 10 years in long-term care, accumulating costs that deplete a state’s Medicaid reserves. The warning is stark—without efficiency improvements or new prevention strategies, dementia care will consume an ever-larger slice of state health budgets.
The Hidden Burden: What Families Actually Pay
The $405,262 lifetime cost figure masks a brutal reality: families pay for roughly 70% of dementia care through unpaid caregiving and out-of-pocket expenses. This is not a policy failure of government—it is the foundation on which dementia care is built. In 2025 alone, unpaid caregivers provided more than 19 billion hours of care valued at $446 billion. To put that in context, if dementia caregivers were paid at even minimum wage ($7.25 per hour), the nation would owe them nearly $138 billion annually just in labor costs. Instead, that work is donated by family members who often sacrifice employment, education, and health to provide it.
Policymakers should recognize that this unpaid care system is fragile and unsustainable. Approximately 70% of dementia caregivers report that coordinating care is stressful, and dementia caregivers experience substantially higher emotional, financial, and physical difficulties than caregivers for people without dementia. A daughter who leaves her job to care for her mother with Alzheimer’s loses not just current income but future Social Security benefits, retirement savings, and career advancement. When that daughter becomes ill or burnt out, the costs suddenly shift to government and paid care—a transition that is often chaotic and expensive. Policymakers investing in caregiver support, respite care, or care coordination might prevent costlier crises later, yet these services are underfunded and inconsistently available across states and regions.
The Budget Reality: Why Current Spending Cannot Continue
The growth trajectory is the real policy problem. At $409 billion in 2026 and projected to reach nearly $1 trillion by 2050, dementia care spending is outpacing overall health spending growth. This is not sustainable without major changes in prevention, treatment efficacy, or how care is financed and delivered. The comparison is instructive: the entire Veterans Health Administration spends roughly $300 billion annually on 9 million veterans. Dementia care alone will soon exceed that for roughly 6 million Americans living with the disease today.
If current trends continue, dementia will consume a larger share of Medicare and Medicaid than any single disease category except perhaps heart disease. What makes this especially challenging for policymakers is that the cost growth is driven by factors they cannot easily control—population aging, longer survival after diagnosis, and the lack of curative or dramatically disease-modifying treatments for most patients. Even the recent approval of lecanemab (Leqembi), a disease-modifying drug that slows cognitive decline, adds cost without eliminating care needs. A person treated with lecanemab still requires caregiving, still develops behavioral and functional problems, and still may eventually enter institutional care. The warning for policymakers is that new medications, while valuable, should not be expected to solve the cost problem. They may actually increase total costs by extending the disease course and the period of care.
Medicare Coverage: What It Includes and What Families Must Pay Separately
Medicare covers certain aspects of dementia care—hospitalization, diagnostic tests, medications, and primary care—but not custodial or non-medical care. This gap is significant for families. Medicare does not pay for bathing, dressing, meal preparation, transportation, or daily supervision, even though these are often the largest cost items in dementia care. A family needing in-home help with these tasks must either rely on informal (unpaid) care or hire it privately at costs ranging from $20 to $50 per hour for basic assistance, or $100+ per hour for skilled nursing. Over months and years, these costs accumulate rapidly.
The 2026 Medicare program does include some policy updates that matter for dementia. The out-of-pocket cap on prescription drugs is set at $2,100 annually, which reduces catastrophic costs for expensive dementia medications. Coverage of lecanemab (Leqembi), the new anti-amyloid monoclonal antibody, falls under a special “Coverage with Evidence Development” program that requires patients to be enrolled in a CMS-approved registry or clinical trial. This means Medicare will pay for the drug, but only under strict conditions and with mandatory data collection. Policymakers should understand this approach as a model for managing expensive new treatments: the government pays but demands real-world evidence that the drug works in diverse populations and that it improves outcomes relative to cost. This is both progressive (ensuring access) and fiscally prudent (requiring accountability).
Medicaid and Long-Term Care: The Program That Bears the Heaviest Load
Medicaid, not Medicare, is the primary payer for long-term dementia care, especially institutional care. For a person whose assets are exhausted and income is limited, Medicaid covers nursing home care, assisted living (in some states), and in-home care services. Medicaid spending on dementia care is substantial and growing, but eligibility and benefit rules vary widely by state, creating a patchwork system that is difficult for policymakers to coordinate nationally. A critical limitation for policymakers is that Medicaid is a joint federal-state program.
States design their own benefits, set their own eligibility thresholds, and bear much of the cost growth through their general revenues. A state experiencing rapid aging and rising dementia prevalence faces a Medicaid budget crisis independently—there is no automatic federal scaling of support. This creates perverse incentives: states may restrict benefits, cut provider rates, or use cost-shifting strategies to manage their budgets, which ultimately harms access and workforce stability. Policymakers at the state level must choose between fully funding dementia care or underfunding it and watching quality decline. Federal policymakers, meanwhile, cannot easily control state-level costs without either funding increases or tight regulatory constraints that may be politically difficult.
Federal Policy and Research Investment: The Case for Prevention
In response to the growing dementia burden, federal policymakers have begun investing more in research and coordination. For fiscal year 2026, the Senate Appropriations Committee approved a $100 million increase in funding for Alzheimer’s and dementia research at the National Institutes of Health, bringing total annual funding to $3.9 billion. This is meaningful but modest relative to the disease burden—it represents less than 1% of total dementia costs. The underlying rationale is that investments in prevention and early treatment might eventually reduce incidence or slow progression, avoiding far larger costs downstream.
The NAPA (National Alzheimer’s Project Act) Authorization Act, signed into law in October 2024, provides a policy framework for coordinating federal planning and programs through 2035. This gives researchers and agencies a longer planning horizon and reflects bipartisan recognition that dementia is a national priority. However, the authorization does not guarantee funding increases or specific policy changes—it establishes coordination mechanisms and sets goals. Policymakers should understand that research funding, while growing, remains insufficient to drive breakthrough discoveries in prevention or disease modification at the scale needed to arrest cost growth. More funding alone is unlikely to solve the problem; fundamental innovations in how care is organized and financed are also necessary.
Coverage Gaps and the Out-of-Pocket Reality
Even with Medicare and Medicaid, families face significant out-of-pocket costs for dementia care. Adult day programs, respite care, some home modifications, transportation, and in-home aides not covered by insurance represent direct expenses that fall to families. A family using an in-home caregiver at $30 per hour for 40 hours per week will pay over $62,000 annually out of pocket—a sum that exceeds the annual income of many American families. Some families delay seeking care or cobble together informal arrangements to avoid these costs, which often leads to worse health outcomes and emergency care that is more expensive.
Policymakers should recognize that the $103 billion in out-of-pocket dementia costs projected for 2026 represents a transfer of risk from public programs to private households. This is particularly regressive—lower-income families are more likely to rely on Medicaid, which covers more services, while middle-income families often have too many assets to qualify for Medicaid but insufficient income to easily afford supplemental private care. Medicare does not cover most long-term care services, so affluent seniors must either spend down to Medicaid eligibility or purchase long-term care insurance (which is increasingly expensive and difficult to obtain). The coverage gap for non-medical care is not an oversight—it reflects long-standing policy that distinguishes between medical care (government’s responsibility) and personal assistance (family or market responsibility). But this distinction becomes unrealistic and cruel when applied to advanced dementia, where medical and non-medical needs are inseparable.
